The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte, MD, Federal University of Ceara Clinical Hospital, Fortaleza, Brazil, shares findings from a Brazilian registry study conducted in partnership with the CIBMTR, which investigated the outcomes of allogeneic stem cell transplantation (alloSCT) in elderly patients (over 60 years of age) with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Duarte emphasizes the importance of comprehensive geriatric assessment to guide patient selection for alloSCT based on physiological age rather than chronological age. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This publication is related to our Brazilian Registry in the partnership of CIBMTR. And it’s more than 400 patients with acute myeloid leukemia, myelodysplastic leukemia, and myeloproliferative disease that we studied specifically the outcomes of these patients. And first that because we have some challenges related to the bone marrow transplantation in patients with more than 60 years...
This publication is related to our Brazilian Registry in the partnership of CIBMTR. And it’s more than 400 patients with acute myeloid leukemia, myelodysplastic leukemia, and myeloproliferative disease that we studied specifically the outcomes of these patients. And first that because we have some challenges related to the bone marrow transplantation in patients with more than 60 years. And then we should emphasize the necessity of comprehensive geriatric assessment to select these patients. And we should do this and it can put the patients not only in the chronological age, but in the physiological age and you should pay attention to this aspect. And another point is that our results, of course it’s a retrospective study, but our results with the haploidentical transplantation were inferior to unrelated donors and related donors. Then we should emphasize this point, that’s because not all countries, specifically in the public system, in Brazil, of course, we don’t have access to the preventive CMV with letermovir. Then probably it could impact the results of haploidentical transplantation.
In summary, we can say that it’s possible to transplant patients with more than 60 years. It’s important. We should try to find patients in the best condition, but you cannot just select this patient based on chronological age. You should emphasize the necessity of comprehensive geriatric assessment to decide for this transplant. And in the second point, the most important, is that we should try to put these patients in the bone marrow transplantation because it’s the only curative option that they have.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
